Navigation Links
Frequently prescribed drug used in concerning ways with harmful side effects
Date:2/6/2013

TORONTO, Feb. 6, 2013A popular class of drugs commonly used to treat sleep and mood symptoms continues to be frequently prescribed despite being known to have potentially life-threatening side effects.

Previous studies have linked benzodiazepines a medication class that may be used in chronic obstructive pulmonary disease (COPD) to treat symptoms of insomnia, depression, anxiety and shortness of breath with adverse outcomes, but until now there has been little information on how frequently it's prescribed or who is using it.

COPD, also known as emphysema or chronic bronchitis, is most commonly caused by smoking in North America and is estimated to affect 5 to10 per cent of the Canadian population. American Thoracic Society-European Respiratory Society guidelines recommend that benzodiazepines be avoided in these patients because of potential respiratory-related side-effects.

Dr. Nicholas Vozoris is the lead author of a study published this week in Drugs and Aging looking at the scope of benzodiazepine use in the older adult COPD population to determine just how many people are using the drug.

"I see a large number of COPD patients taking this medication class to help relieve disease-related symptoms like insomnia, depression and anxiety," said Dr. Vozoris, a respirologist at St. Michael's Hospital. "But considering the potential respiratory side-effects, and the well-documented neurocognitive side effects like memory loss, decreased alertness, falls and increased risk of motor vehicle accidents, the high frequency of benzodiazepine use in COPD is very concerning."

Dr. Vozoris and colleagues looked at more than 100,000 adults 66 years and older with COPD in Ontario between 2004 and 2009 to see how many new benzodiazepines were dispensed and the severity of each patients' COPD while on the drug.

The results found that new benzodiazepine dispensing was common and occurred in more than a third of the adults. Use of the drugs was 40 per cent more common amongst those with more severe COPD. This group also had the highest number of repeat prescriptions and early refills and benzodiazepines were also commonly dispensed to patients while they were having flare-ups of the disease.

"These findings are new and they are concerning because they tell us that the patients most at risk to be affected by the adverse effects of this drug are the same ones that are using it with the most frequency," Dr. Vozoris said. "This medication could be causing harm in this already respiratory-vulnerable population."

Although benzodiazepines can be effective for helping patients sleep, this medication class has been previously found to affect breathing ability and oxygen levels at night.

"Patients need to hear this and health care providers need to give thought into who they are prescribing this medication class to," Dr. Vozoris said. "We're talking about a very vulnerable sub-group and we may be inappropriately prescribing this medication class to those patients."


'/>"/>

Contact: Kate Taylor
TaylorKa@smh.ca
647-393-7527
St. Michael's Hospital
Source:Eurekalert

Related medicine news :

1. UC Davis study finds stray-bullet shootings frequently harm women and children
2. Black patients with hypertension not prescribed diuretics enough
3. New UAlberta research shows commonly prescribed medications could have adverse effects
4. More U.S. Kids Prescribed Off-Label Antipsychotics: Study
5. New federal disclosure law may have little impact on drugs prescribed
6. Not taking gastroprotective drugs prescribed with anti-inflammatory medicines
7. Fitness Expert Lorna Kleidman Comments on Article Concerning Weight Loss as a New Year’s Resolution
8. Lorna Kleidman Responds to an Article Concerning Military Weight Loss
9. Transvaginal Mesh Lawsuit Update: New Study Concerning Use of Vaginal Mesh in Prolapse Procedures, Bernstein Liebhard LLP Reports
10. New test predicted presence of harmful BRCA mutations
11. Harmful effects of bisphenol A proved experimentally
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... ... January 20, 2017 , ... Spectrum Aquatics Launches New ADA Portable Motion Trek BP 300 ... the lift is mounted on wheels, it can be wheeled out of the way and ... fasten to the deck. "We have transformed the feedback from customers into specific enhancements and ...
(Date:1/20/2017)... ... 20, 2017 , ... Source Vitál Apothecary, a skin and body care company ... the company had a successful visit to the 2017 ECRM Diet, Vitamin & Sports ... work in the nutritional, sports and health industries a chance to meet in private ...
(Date:1/20/2017)... Florida (PRWEB) , ... January 20, 2017 , ... Lice ... head lice cases in families with school-aged children since the holiday season. , ... the holidays with their families, sharing hugs and taking photos, which is the head-to-head ...
(Date:1/20/2017)... ... January 20, 2017 , ... Michael and Betsy Brauser celebrated 5 years of ... the clinical trial has been life-saving as she has been on the trial ... Brauser was diagnosed with ovarian cancer in 2009. She underwent standard chemotherapy but a ...
(Date:1/20/2017)... ... 20, 2017 , ... “Mary Magdalene: Grace is Greater than Sin”: a ... witnessed Jesus Christ firsthand. “Mary Magdalene: Grace is Greater than Sin” is the creation ... educator interacting with countless women who had little knowledge of the female characters portrayed ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... -- Accuray Incorporated (Nasdaq: ARAY ) announced ... set the bar for excellence in customer satisfaction. The ... rating among radiation treatment delivery systems in the U.S., ... Briefing™. The most recent ratings trend also shows Accuray ... for 11 of the past 12 quarters. ...
(Date:1/19/2017)... CLEVELAND , Jan. 19, 2017 ViewRay, ... (DFG), a federal institution supporting research in ... installation and patient treatments at the University Clinic Heidelberg ... The MRIdian Linac program will be headed ... who also heads radiation oncology at the German Cancer ...
(Date:1/19/2017)... , January 19, 2017 ... Option to Address Motor Symptoms and Motor Complications ... ...      (Logo: http://photos.prnewswire.com/prnh/20151014/276718LOGO) ... , European Neurological Review,2016;11(Suppl. 2): 2-15, http://www.touchneurology.com/articles/safinamide-new-therapeutic-option-address-motor-symptoms-and-motor-complications-mid-late ...
Breaking Medicine Technology: